Lonza refines long-term growth strategy, shares tracked against European health peers

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-28, 11:38.

Lonza Group AG (CH0013841017) is a key name in European healthcare outsourcing, with its shares listed on the SIX Swiss Exchange in Zurich. Investors continue to assess Lonza’s long-term positioning in biologics and small-molecule contract development relative to sector peers such as Sartorius and Catalent, according to recent market commentary from UBS and other banks.

Lonza in the European healthcare landscape

Lonza operates in the global contract development and manufacturing organization segment, supplying development and production services to pharmaceutical and biotechnology companies across Europe, North America and Asia. The company is often grouped with European life science suppliers like Sartorius and Merck KGaA in sector reviews of healthcare outsourcing and bioprocessing.

Analysts at UBS and other houses regularly cite Lonza’s exposure to biologics, cell and gene therapy capacity and its role in filling and finishing treatments as reasons for sustained interest in the stock, even when sentiment in the broader healthcare sector is mixed.

Focus on long-term growth drivers

Lonza’s strategy emphasizes investment in biologics manufacturing capacity, cell and gene technologies and targeted small-molecule services to capture structural growth in outsourced pharmaceutical production. The company reports that it continues to expand capacity and capabilities to support customers from early development through commercial manufacturing across multiple regions.

The Swiss group also highlights demand from large pharmaceutical companies and emerging biotech firms for development, manufacturing and technical services, with long-term contracts and multi-year supply agreements an important element of revenue visibility.

How Lonza generates revenue

Lonza primarily earns its revenue by providing development and manufacturing services for active pharmaceutical ingredients, biologics and cell and gene therapies to global pharmaceutical and biotechnology companies. It also offers related services such as formulation, analytical testing and regulatory support along the value chain.

Where the shares trade today

The Lonza Group AG shares (CH0013841017) trade on the SIX Swiss Exchange in Zurich, with prices quoted in Swiss francs. On 2026-06-28, 11:30, the shares last changed hands at 577.20 CHF.

This article is for informational purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any financial instrument. Investors should conduct their own research or consult a qualified advisor before making investment decisions.